Back to Search
Start Over
Randomized controlled trial of 2 prenatal iron supplements: is there a dose-response relation with maternal hemoglobin?
- Publication Year :
- 2011
-
Abstract
- Background: The most appropriate dose of iron to prevent maternal anemia is still unclear. Objective: We assessed the dose-response relation between maternal hemoglobin and 2 prenatal iron supplements. Design: An intention-to-treat, double-blind, randomized controlled trial compared 30 mg Fe + folic acid and 13 other micronutrients (UNIMMAP; UNICEF/WHO/UNU multiple micronutrient supplement for pregnant and lactating women) with 60 mg Fe + folic acid (IFA) only in rural Burkina Faso. Home visitors directly observed tablet intake. Mixed-effects models were used for the data analysis. Results: At inclusion, 43.2% of the 1268 participants were anemic. On average, the hemoglobin concentration decreased over gestation by 0.019 g/dL (95% CI: 0.012, 0.025 g/dL) per week in the IFA and UNIMMAP groups. An increment in hemoglobin concentration per micronutrient tablet [b (6SE) = 0.006 6 0.001 g/dL; P , 0001] was observed only in women who were anemic at inclusion, whereas a decrease was observed in the other mothers (20.003 6 0.001 g/dL; P = 0.002, P for interaction , 0.0001); the finding was similar in both the IFA and UNIMMAP groups. Women with baseline anemia achieved the same hemoglobin concentration (mean 6 SD: 11.1 6 0.64 g/dL) as their counterparts who received 6180 tablets of either UNIMMAP or IFA. Despite this, micronutrient intake did not significantly prevent anemia (51.0% in the third trimester). It was, however, a risk factor for hemoconcentration (odds ratio per tertile of tablet intake: 2.10; 95% CI: 1.12, 3.94), independently of supplement type or initial hemoglobin concentration. Conclusions: UNIMMAP triggered the same hemoglobin dose response with half the amount of iron as provided by IFA treatment. The benefit of iron supplements in nonanemic women is unclear. Despite micronutrient supplementation, anemia remained highly prevalent during gestation, partly because of physiologic hemodilution. This trial was registered at clinicaltrials.gov as NCT00642408. Am J Clin Nutr 2011;93:1012‐8.
- Subjects :
- Africa, West
Folic acid
medicine.medical_treatment
Medicine (miscellaneous)
Physiology
Maternal
Hemoglobins
Nutritional status
Risk Factors
Pregnancy
Prevalence
Medicine
Prenatal
Hemoglobin concentration
Micronutrients
Prenatal Nutritional Physiological Phenomena
Nutrition and Dietetics
Anemia, Iron-Deficiency
Anemia
Iron deficiency
Micronutrient
Randomized controlled trials
Gestation
Female
Adult
Adolescent
Iron
Iron supplement
Prenatal care
Young Adult
Double-Blind Method
Burkina Faso
Humans
Nutrition disorders
Women
Hemoglobin
Iron supplementation
Dose-Response Relationship, Drug
business.industry
Prevention
Pregnancy Complications, Hematologic
medicine.disease
Directly Observed Therapy
Immunology
Dietary Supplements
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....358a163b5772d4526a3701c09a8589ff